Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV)
CUSIP: 004890109
Q1 2023 13F Holders as of 31 Mar 2023
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 42,655,924
- Total 13F shares
- 15,216,182
- Share change
- +534,746
- Total reported value
- $191,059,725
- Price per share
- $12.69
- Number of holders
- 39
- Value change
- +$6,824,894
- Number of buys
- 31
- Number of sells
- 7
Quarterly Holders Quick Answers
What is CUSIP 004890109?
CUSIP 004890109 identifies ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 004890109:
Top shareholders of ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
11%
|
4,810,508
|
$55,417,052 | — | 31 Dec 2022 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
7.1%
|
3,007,858
|
$34,650,524 | — | 31 Dec 2022 | |
| Sands Capital Alternatives, LLC |
13F
|
Company |
3.9%
|
1,652,605
|
$19,038,000 | — | 31 Dec 2022 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
3.8%
|
1,634,104
|
$18,211,002 | — | 31 Dec 2022 | |
| MARSHALL WACE, LLP |
13F
|
Company |
2.9%
|
1,223,252
|
$14,091,863 | — | 31 Dec 2022 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2.1%
|
900,149
|
$9,994,103 | — | 31 Dec 2022 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
1.9%
|
823,300
|
$9,484,416 | — | 31 Dec 2022 | |
| NEA Management Company, LLC |
13F
|
Company |
1.1%
|
481,677
|
$4,439,135 | — | 31 Dec 2022 | |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
888,130
|
$3,863,366 | — | 17 Nov 2022 | |
| HealthCor Management, L.P. |
13F
|
Company |
0.67%
|
284,201
|
$3,273,995 | — | 31 Dec 2022 | |
| BANK OF MONTREAL /CAN/ |
13F
|
Company |
0.1%
|
42,444
|
$544,981 | — | 31 Dec 2022 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.09%
|
38,800
|
$446,976 | — | 31 Dec 2022 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.05%
|
21,534
|
$248,072 | — | 31 Dec 2022 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.05%
|
19,639
|
$226,000 | — | 31 Dec 2022 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.04%
|
15,648
|
$180,265 | — | 31 Dec 2022 | |
| UBS Group AG |
13F
|
Company |
0.01%
|
4,748
|
$54,697 | — | 31 Dec 2022 | |
| BARCLAYS PLC |
13F
|
Company |
0.01%
|
4,142
|
$47,716 | — | 31 Dec 2022 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
869
|
$10,011 | — | 31 Dec 2022 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
159
|
$2,000 | — | 31 Dec 2022 |
Institutional Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) as of Q1 2023
As of 31 Mar 2023,
Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) was held by
39 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,216,182 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., PERCEPTIVE ADVISORS LLC, Sands Capital Ventures, LLC, CITADEL ADVISORS LLC, WELLINGTON MANAGEMENT GROUP LLP, FEDERATED HERMES, INC., MARSHALL WACE, LLP, NEA Management Company, LLC, BlackRock Inc., and VANGUARD GROUP INC.
This page lists
39
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2023 vs Q4 2022 Across Filers
Q4 2022 holders
18
Q1 2023 holders
39
Holder diff
21
| Investor | Q4 2022 Shares | Q1 2023 Shares | Share Diff | Share Chg % | Q4 2022 Value $ | Q1 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.